The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Active Pharmaceutical Ingredients CDMO Market Research Report 2024
Synopsis
contract manufacturing organization (CMO), sometimes called a contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing.
The global Active Pharmaceutical Ingredients CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Active Pharmaceutical Ingredients CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Active Pharmaceutical Ingredients CDMO.
Report Scope
The Active Pharmaceutical Ingredients CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Active Pharmaceutical Ingredients CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Active Pharmaceutical Ingredients CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cambrex
Recipharm
Thermo Fisher Pantheon
Corden Pharma
Samsung Biologics
Lonza
Catalent
Siegfried
Piramal Pharma Solutions
Boehringer Ingelheim
Segment by Type
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC)
Others
Segment by Application
Oncology
Hormonal
Glaucoma
Cardiovascular
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Active Pharmaceutical Ingredients CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
contract manufacturing organization (CMO), sometimes called a contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing.
The global Active Pharmaceutical Ingredients CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Active Pharmaceutical Ingredients CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Active Pharmaceutical Ingredients CDMO.
Report Scope
The Active Pharmaceutical Ingredients CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Active Pharmaceutical Ingredients CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Active Pharmaceutical Ingredients CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cambrex
Recipharm
Thermo Fisher Pantheon
Corden Pharma
Samsung Biologics
Lonza
Catalent
Siegfried
Piramal Pharma Solutions
Boehringer Ingelheim
Segment by Type
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC)
Others
Segment by Application
Oncology
Hormonal
Glaucoma
Cardiovascular
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Active Pharmaceutical Ingredients CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Traditional Active Pharmaceutical Ingredient (Traditional API)
1.2.3 Highly Potent Active Pharmaceutical Ingredient (HP-API)
1.2.4 Antibody Drug Conjugate (ADC)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Active Pharmaceutical Ingredients CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Hormonal
1.3.4 Glaucoma
1.3.5 Cardiovascular
1.3.6 Diabetes
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Active Pharmaceutical Ingredients CDMO Market Perspective (2019-2030)
2.2 Active Pharmaceutical Ingredients CDMO Growth Trends by Region
2.2.1 Global Active Pharmaceutical Ingredients CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Active Pharmaceutical Ingredients CDMO Historic Market Size by Region (2019-2024)
2.2.3 Active Pharmaceutical Ingredients CDMO Forecasted Market Size by Region (2025-2030)
2.3 Active Pharmaceutical Ingredients CDMO Market Dynamics
2.3.1 Active Pharmaceutical Ingredients CDMO Industry Trends
2.3.2 Active Pharmaceutical Ingredients CDMO Market Drivers
2.3.3 Active Pharmaceutical Ingredients CDMO Market Challenges
2.3.4 Active Pharmaceutical Ingredients CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Active Pharmaceutical Ingredients CDMO Players by Revenue
3.1.1 Global Top Active Pharmaceutical Ingredients CDMO Players by Revenue (2019-2024)
3.1.2 Global Active Pharmaceutical Ingredients CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Active Pharmaceutical Ingredients CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Active Pharmaceutical Ingredients CDMO Revenue
3.4 Global Active Pharmaceutical Ingredients CDMO Market Concentration Ratio
3.4.1 Global Active Pharmaceutical Ingredients CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Active Pharmaceutical Ingredients CDMO Revenue in 2023
3.5 Active Pharmaceutical Ingredients CDMO Key Players Head office and Area Served
3.6 Key Players Active Pharmaceutical Ingredients CDMO Product Solution and Service
3.7 Date of Enter into Active Pharmaceutical Ingredients CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Active Pharmaceutical Ingredients CDMO Breakdown Data by Type
4.1 Global Active Pharmaceutical Ingredients CDMO Historic Market Size by Type (2019-2024)
4.2 Global Active Pharmaceutical Ingredients CDMO Forecasted Market Size by Type (2025-2030)
5 Active Pharmaceutical Ingredients CDMO Breakdown Data by Application
5.1 Global Active Pharmaceutical Ingredients CDMO Historic Market Size by Application (2019-2024)
5.2 Global Active Pharmaceutical Ingredients CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Active Pharmaceutical Ingredients CDMO Market Size (2019-2030)
6.2 North America Active Pharmaceutical Ingredients CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024)
6.4 North America Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Active Pharmaceutical Ingredients CDMO Market Size (2019-2030)
7.2 Europe Active Pharmaceutical Ingredients CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024)
7.4 Europe Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size (2019-2030)
8.2 Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Active Pharmaceutical Ingredients CDMO Market Size (2019-2030)
9.2 Latin America Active Pharmaceutical Ingredients CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024)
9.4 Latin America Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size (2019-2030)
10.2 Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cambrex
11.1.1 Cambrex Company Detail
11.1.2 Cambrex Business Overview
11.1.3 Cambrex Active Pharmaceutical Ingredients CDMO Introduction
11.1.4 Cambrex Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.1.5 Cambrex Recent Development
11.2 Recipharm
11.2.1 Recipharm Company Detail
11.2.2 Recipharm Business Overview
11.2.3 Recipharm Active Pharmaceutical Ingredients CDMO Introduction
11.2.4 Recipharm Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.2.5 Recipharm Recent Development
11.3 Thermo Fisher Pantheon
11.3.1 Thermo Fisher Pantheon Company Detail
11.3.2 Thermo Fisher Pantheon Business Overview
11.3.3 Thermo Fisher Pantheon Active Pharmaceutical Ingredients CDMO Introduction
11.3.4 Thermo Fisher Pantheon Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.3.5 Thermo Fisher Pantheon Recent Development
11.4 Corden Pharma
11.4.1 Corden Pharma Company Detail
11.4.2 Corden Pharma Business Overview
11.4.3 Corden Pharma Active Pharmaceutical Ingredients CDMO Introduction
11.4.4 Corden Pharma Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.4.5 Corden Pharma Recent Development
11.5 Samsung Biologics
11.5.1 Samsung Biologics Company Detail
11.5.2 Samsung Biologics Business Overview
11.5.3 Samsung Biologics Active Pharmaceutical Ingredients CDMO Introduction
11.5.4 Samsung Biologics Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.5.5 Samsung Biologics Recent Development
11.6 Lonza
11.6.1 Lonza Company Detail
11.6.2 Lonza Business Overview
11.6.3 Lonza Active Pharmaceutical Ingredients CDMO Introduction
11.6.4 Lonza Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.6.5 Lonza Recent Development
11.7 Catalent
11.7.1 Catalent Company Detail
11.7.2 Catalent Business Overview
11.7.3 Catalent Active Pharmaceutical Ingredients CDMO Introduction
11.7.4 Catalent Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.7.5 Catalent Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Detail
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Active Pharmaceutical Ingredients CDMO Introduction
11.8.4 Siegfried Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.8.5 Siegfried Recent Development
11.9 Piramal Pharma Solutions
11.9.1 Piramal Pharma Solutions Company Detail
11.9.2 Piramal Pharma Solutions Business Overview
11.9.3 Piramal Pharma Solutions Active Pharmaceutical Ingredients CDMO Introduction
11.9.4 Piramal Pharma Solutions Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.9.5 Piramal Pharma Solutions Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Detail
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Active Pharmaceutical Ingredients CDMO Introduction
11.10.4 Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
11.10.5 Boehringer Ingelheim Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Traditional Active Pharmaceutical Ingredient (Traditional API)
Table 3. Key Players of Highly Potent Active Pharmaceutical Ingredient (HP-API)
Table 4. Key Players of Antibody Drug Conjugate (ADC)
Table 5. Key Players of Others
Table 6. Global Active Pharmaceutical Ingredients CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Active Pharmaceutical Ingredients CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Active Pharmaceutical Ingredients CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Active Pharmaceutical Ingredients CDMO Market Share by Region (2019-2024)
Table 10. Global Active Pharmaceutical Ingredients CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Active Pharmaceutical Ingredients CDMO Market Share by Region (2025-2030)
Table 12. Active Pharmaceutical Ingredients CDMO Market Trends
Table 13. Active Pharmaceutical Ingredients CDMO Market Drivers
Table 14. Active Pharmaceutical Ingredients CDMO Market Challenges
Table 15. Active Pharmaceutical Ingredients CDMO Market Restraints
Table 16. Global Active Pharmaceutical Ingredients CDMO Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Active Pharmaceutical Ingredients CDMO Market Share by Players (2019-2024)
Table 18. Global Top Active Pharmaceutical Ingredients CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients CDMO as of 2023)
Table 19. Ranking of Global Top Active Pharmaceutical Ingredients CDMO Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Active Pharmaceutical Ingredients CDMO Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Active Pharmaceutical Ingredients CDMO Product Solution and Service
Table 23. Date of Enter into Active Pharmaceutical Ingredients CDMO Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Active Pharmaceutical Ingredients CDMO Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Active Pharmaceutical Ingredients CDMO Revenue Market Share by Type (2019-2024)
Table 27. Global Active Pharmaceutical Ingredients CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Active Pharmaceutical Ingredients CDMO Revenue Market Share by Type (2025-2030)
Table 29. Global Active Pharmaceutical Ingredients CDMO Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Active Pharmaceutical Ingredients CDMO Revenue Market Share by Application (2019-2024)
Table 31. Global Active Pharmaceutical Ingredients CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Active Pharmaceutical Ingredients CDMO Revenue Market Share by Application (2025-2030)
Table 33. North America Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 48. Cambrex Company Detail
Table 49. Cambrex Business Overview
Table 50. Cambrex Active Pharmaceutical Ingredients CDMO Product
Table 51. Cambrex Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 52. Cambrex Recent Development
Table 53. Recipharm Company Detail
Table 54. Recipharm Business Overview
Table 55. Recipharm Active Pharmaceutical Ingredients CDMO Product
Table 56. Recipharm Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 57. Recipharm Recent Development
Table 58. Thermo Fisher Pantheon Company Detail
Table 59. Thermo Fisher Pantheon Business Overview
Table 60. Thermo Fisher Pantheon Active Pharmaceutical Ingredients CDMO Product
Table 61. Thermo Fisher Pantheon Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 62. Thermo Fisher Pantheon Recent Development
Table 63. Corden Pharma Company Detail
Table 64. Corden Pharma Business Overview
Table 65. Corden Pharma Active Pharmaceutical Ingredients CDMO Product
Table 66. Corden Pharma Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 67. Corden Pharma Recent Development
Table 68. Samsung Biologics Company Detail
Table 69. Samsung Biologics Business Overview
Table 70. Samsung Biologics Active Pharmaceutical Ingredients CDMO Product
Table 71. Samsung Biologics Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 72. Samsung Biologics Recent Development
Table 73. Lonza Company Detail
Table 74. Lonza Business Overview
Table 75. Lonza Active Pharmaceutical Ingredients CDMO Product
Table 76. Lonza Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 77. Lonza Recent Development
Table 78. Catalent Company Detail
Table 79. Catalent Business Overview
Table 80. Catalent Active Pharmaceutical Ingredients CDMO Product
Table 81. Catalent Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 82. Catalent Recent Development
Table 83. Siegfried Company Detail
Table 84. Siegfried Business Overview
Table 85. Siegfried Active Pharmaceutical Ingredients CDMO Product
Table 86. Siegfried Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 87. Siegfried Recent Development
Table 88. Piramal Pharma Solutions Company Detail
Table 89. Piramal Pharma Solutions Business Overview
Table 90. Piramal Pharma Solutions Active Pharmaceutical Ingredients CDMO Product
Table 91. Piramal Pharma Solutions Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 92. Piramal Pharma Solutions Recent Development
Table 93. Boehringer Ingelheim Company Detail
Table 94. Boehringer Ingelheim Business Overview
Table 95. Boehringer Ingelheim Active Pharmaceutical Ingredients CDMO Product
Table 96. Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients CDMO Business (2019-2024) & (US$ Million)
Table 97. Boehringer Ingelheim Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Active Pharmaceutical Ingredients CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Active Pharmaceutical Ingredients CDMO Market Share by Type: 2023 VS 2030
Figure 3. Traditional Active Pharmaceutical Ingredient (Traditional API) Features
Figure 4. Highly Potent Active Pharmaceutical Ingredient (HP-API) Features
Figure 5. Antibody Drug Conjugate (ADC) Features
Figure 6. Others Features
Figure 7. Global Active Pharmaceutical Ingredients CDMO Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Active Pharmaceutical Ingredients CDMO Market Share by Application: 2023 VS 2030
Figure 9. Oncology Case Studies
Figure 10. Hormonal Case Studies
Figure 11. Glaucoma Case Studies
Figure 12. Cardiovascular Case Studies
Figure 13. Diabetes Case Studies
Figure 14. Others Case Studies
Figure 15. Active Pharmaceutical Ingredients CDMO Report Years Considered
Figure 16. Global Active Pharmaceutical Ingredients CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Active Pharmaceutical Ingredients CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Active Pharmaceutical Ingredients CDMO Market Share by Region: 2023 VS 2030
Figure 19. Global Active Pharmaceutical Ingredients CDMO Market Share by Players in 2023
Figure 20. Global Top Active Pharmaceutical Ingredients CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients CDMO as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Active Pharmaceutical Ingredients CDMO Revenue in 2023
Figure 22. North America Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Active Pharmaceutical Ingredients CDMO Market Share by Country (2019-2030)
Figure 24. United States Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Active Pharmaceutical Ingredients CDMO Market Share by Country (2019-2030)
Figure 28. Germany Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Share by Region (2019-2030)
Figure 36. China Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Active Pharmaceutical Ingredients CDMO Market Share by Country (2019-2030)
Figure 44. Mexico Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Share by Country (2019-2030)
Figure 48. Turkey Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Cambrex Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 51. Recipharm Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 52. Thermo Fisher Pantheon Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 53. Corden Pharma Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 54. Samsung Biologics Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 55. Lonza Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 56. Catalent Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 57. Siegfried Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 58. Piramal Pharma Solutions Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 59. Boehringer Ingelheim Revenue Growth Rate in Active Pharmaceutical Ingredients CDMO Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
